Global Toxicology Services Market Outlook 2021-2028 by Study Method, Industry, End-Point and Region
25 nov. 2021 05h23 HE
|
Research and Markets
Dublin, Nov. 25, 2021 (GLOBE NEWSWIRE) -- The "Toxicology Services Global Market - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering. According to analysis, the global...
Global microRNA 21 (MIR21) Drugs Development Market Report 2021
29 avr. 2021 08h13 HE
|
Research and Markets
Dublin, April 29, 2021 (GLOBE NEWSWIRE) -- The "microRNA 21 (MIR21) - Drugs in Development, 2021" report has been added to ResearchAndMarkets.com's offering. microRNA 21 (MIR21) - Drugs in...
Global Orphan Drugs Markets, 2019-2020 & 2025 - AI-powered Early Disease Diagnosis and Drug Repurposing will Create New Growth Opportunities
09 nov. 2020 04h48 HE
|
Research and Markets
Dublin, Nov. 09, 2020 (GLOBE NEWSWIRE) -- The "New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019-2025" report has been added to...
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD Studies
31 juil. 2019 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 31, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments Nintedanib and Pirfenidone
03 juil. 2019 07h00 HE
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 03, 2019 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”), a clinical stage pharmaceutical...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results Showing Lead Compound NP-160 Significantly Reduces NALFD Score and Fibrosis in Non-Alcoholic Fatty Liver Disease
01 nov. 2018 07h00 HE
|
Breathtec Biomedical Inc.
Planning Phase II Trial VANCOUVER, B.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...